Gene Expression Profiling for UIP Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing idiopathic pulmonary fibrosis (IPF) are invasive, unreliable, and often require surgical lung biopsy, with high complication rates and lengthy diagnostic processes, due to challenges in distinguishing usual interstitial pneumonia (UIP) from non-UIP patterns, especially in transbronchial biopsies with heterogeneous disease distribution and cellular heterogeneity.
Innovation Solution
The use of gene expression profiling methods that detect mRNA levels in lung tissue samples to differentiate between UIP and non-UIP patterns through classifiers trained on datasets including various ILD subtypes, utilizing physical or in silico pooling to enhance sensitivity and specificity, and being agnostic to cellular heterogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical lung biopsy is performed to confirm UIP pattern, then diagnostic reliability is improved, but patient harm increases due to high complication rates and mortality
Solution Approach 1:
The patent replaces the mechanical surgical lung biopsy procedure with a molecular diagnostic system that analyzes gene expression profiles from transbronchial biopsy samples. This substitution eliminates the need for invasive surgical procedures while maintaining diagnostic accuracy through computational analysis of molecular markers that distinguish UIP from other interstitial lung diseases.
Solution Approach 2:
The patent introduces gene expression profiling as an intermediary diagnostic tool between clinical suspicion and definitive diagnosis. By analyzing molecular signatures from minimally invasive transbronchial biopsies, the system provides intermediate diagnostic information that can confirm or rule out UIP without requiring the harmful surgical biopsy procedure.
2Object-affected harmful factors
If transbronchial biopsy is used to sample lung tissue, then invasiveness is reduced, but measurement precision deteriorates due to insufficient sampling of alveolated parenchyma
Solution Approach 1:
The patent changes the diagnostic parameter from histopathological evaluation of tissue architecture to molecular gene expression profiling. This parameter transformation allows accurate UIP diagnosis from transbronchial biopsy samples that would be insufficient for traditional histological assessment, as gene expression markers provide molecular-level information that overcomes sampling limitations.
Solution Approach 2:
The patent replaces mechanical histopathological examination with molecular gene expression analysis. This substitution enables precise diagnostic measurement from smaller, less invasive tissue samples by detecting molecular signatures rather than relying on sufficient architectural sampling.
3Reliability
If traditional histopathological evaluation is performed, then diagnostic specificity is maintained, but diagnostic time increases due to heterogeneous disease distribution and sampling variability
Solution Approach 1:
The patent creates a molecular copy or signature of the UIP disease state through gene expression profiling. Instead of requiring extensive tissue sampling to capture heterogeneous disease features, the molecular profile serves as a representative copy that encapsulates the diagnostic information, enabling rapid and specific diagnosis without time-consuming histopathological evaluation.
Solution Approach 2:
The patent transforms the diagnostic parameter from spatial histopathological patterns to temporal gene expression profiles. This parameter change enables diagnosis based on molecular kinetics and expression levels rather than spatial distribution of pathological features, reducing diagnostic time while maintaining specificity.
4Measurement precision
If multiple biopsies are taken to improve sampling adequacy, then measurement precision is improved, but patient harm increases due to repeated invasive procedures
Solution Approach 1:
The patent changes the diagnostic parameter to molecular gene expression levels that can be accurately measured from small tissue samples. This parameter transformation eliminates the need for multiple biopsies to achieve adequate sampling, as molecular markers provide sufficient diagnostic information from minimal tissue, thereby reducing procedural risk.
Solution Approach 2:
The patent uses molecular gene expression profiles as information copies that capture diagnostic essence from minimal tissue. This copying approach allows accurate diagnosis from single small biopsies rather than requiring multiple samples, reducing patient exposure to invasive procedures while maintaining measurement precision.
Data Source
AI summary
The present disclosure provides systems, methods, and classifiers for differentiating between samples as usual interstitial pneumonia (UIP) or non-UIP.